Association between anti-citrullinated alpha enolase antibodies and clinical features in a cohort of patients with rheumatoid arthritis: a pilot study

In recent years several antibodies against citrullinated peptides (ACPAs) have been identified in patients with rheumatoid arthritis (RA) and their pathogenic, diagnostic and prognostic significance is under intense investigation. Among ACPAs, those targeting citrullinated alpha enolase (anti-CEP1)...

Full description

Saved in:
Bibliographic Details
Published in:Reumatismo 2018-07, Vol.70 (2), p.67-71
Main Authors: Alunno, A, Bistoni, O, Pratesi, F, Topini, F, Puxeddu, I, Valentini, V, Cafaro, G, Bartoloni, E, Migliorini, P, Gerli, R
Format: Article
Language:English
Subjects:
Aged
Anti-Citrullinated Protein Antibodies - blood
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - epidemiology
Arthritis, Rheumatoid - immunology
Autoantigens - immunology
Biomarkers
Comorbidity
Humans
Investigations
Lung Diseases, Interstitial - blood
Lung Diseases, Interstitial - epidemiology
Lung Diseases, Interstitial - etiology
Lung Diseases, Interstitial - immunology
Male
Middle Aged
Phosphopyruvate Hydratase - immunology
Pilot Projects
Prognosis
Rheumatoid arthritis
Smoking - epidemiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years several antibodies against citrullinated peptides (ACPAs) have been identified in patients with rheumatoid arthritis (RA) and their pathogenic, diagnostic and prognostic significance is under intense investigation. Among ACPAs, those targeting citrullinated alpha enolase (anti-CEP1) have been identified in RA but data about their ability to predict the development of erosive disease are conflicting. Furthermore, no data are currently available concerning their possible association with extra-articular manifestations (EAMs) in RA. The aim of this study was to investigate the prevalence and significance of anti-CEP1 from a prognostic point of view. In this pilot study we confirmed that anti-CEP1 Abs are associated with higher prevalence of bone erosions, but we also provided the first evidence of an association between anti-CEP1 Abs and RA interstitial lung disease (ILD). These results provide the basis to investigate the association between anti-CEP1 Abs and EAMs in larger cohorts of RA patients to possibly confirm its role as biomarker for RA-ILD.
ISSN:0048-7449
2240-2683
DOI:10.4081/reumatismo.2018.1028